Jerry Molitor is a Rheumatology/Immunology physician affiliated with University of Minnesota. OpenAlex indexes 77 publications with 7,933 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
516 Delaware Street SE, Clinic 6a
Ump Medicine Specialties Clinic
Minneapolis, MN 55455
Telephone
612-884-0649Registry record last updated 31 Oct 2012.
Clinical trials
- Phototherapy For Treatment Of Raynaud's Phenomenon
Sponsor: University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20254 payments
- Boehringer Ingelheim International GmbHProgram year20242 payments
- AstraZeneca Pharmaceuticals LPProgram year202310 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
30.9%Proton pump inhibitor15.5%Omeprazole48%Pantoprazole Sodium28%Esomeprazole Magnesium24%Part D<11 patientsCorticosteroid9.6%Prednisone100%Part D≥18 patients+ 1 more class in this area
Nervous system
16.2%Cholinergic Receptor Agonist11.3%Cevimeline Hcl67%Pilocarpine Hcl33%Part D<11 patientsOpioid Agonist2.7%Tramadol Hcl100%Part D<11 patients+ 1 more class in this area
Antiparasitic
15.9%Antimalarial15.9%Hydroxychloroquine Sulfate100%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The primary cardiomyopathy of systemic sclerosis on cardiovascular magnetic resonance imaging
European Heart Journal - Cardiovascular Imaging
2023 - Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial
American Journal of Respiratory and Critical Care Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”